Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating obinutuzumab, zanubrutinib, and lenalidomide as first-line treatment for mantle cell lymphoma, with the study currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING